» Articles » PMID: 34439438

Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure

Overview
Date 2021 Aug 27
PMID 34439438
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial sodium-glucose cotransporter 1 (SGLT1) has been shown to be upregulated in humans with heart failure (HF) with or without diabetes. In vitro studies have linked SGLT1 to increased nitro-oxidative stress in cardiomyocytes. We aimed to assess the relation between left ventricular (LV) SGLT1 expression and the extent of nitro-oxidative stress in two non-diabetic rat models of chronic heart failure (HF) evoked by either pressure (TAC, = 12) or volume overload (ACF, = 12). Sham-operated animals (Sham-T and Sham-A, both = 12) served as controls. Both TAC and ACF induced characteristic LV structural and functional remodeling. Western blotting revealed that LV SGLT1 protein expression was significantly upregulated in both HF models (both < 0.01), whereas the phosphorylation of ERK1/2 was decreased only in ACF; AMPKα activity was significantly reduced in both models. The protein expression of the Nox4 NADPH oxidase isoform was increased in both TAC and ACF compared with respective controls (both < 0.01), showing a strong positive correlation with SGLT1 expression ( = 0.855, < 0.001; and = 0.798, = 0.001, respectively). Furthermore, SGLT1 protein expression positively correlated with the extent of myocardial nitro-oxidative stress in failing hearts assessed by 3-nitrotyrosin ( = 0.818, = 0.006) and 4-hydroxy-2-nonenal ( = 0.733, = 0.020) immunostaining. Therefore, LV SGLT1 protein expression was upregulated irrespective of the nature of chronic hemodynamic overload, and correlated significantly with the expression of Nox4 and with the level of myocardial nitro-oxidative stress, suggesting a pathophysiological role of SGLT1 in HF.

Citing Articles

SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms.

Chen Y, Zhu F, Zhou R Front Cardiovasc Med. 2024; 11:1494882.

PMID: 39717441 PMC: 11663900. DOI: 10.3389/fcvm.2024.1494882.


The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview.

Ionica L, Linta A, Batrin A, Hancu I, Lolescu B, Danila M Int J Mol Sci. 2024; 25(14).

PMID: 39062954 PMC: 11277154. DOI: 10.3390/ijms25147711.


Xinbao Pill ameliorates heart failure via regulating the SGLT1/AMPK/PPARα axis to improve myocardial fatty acid energy metabolism.

Pan L, Xu Z, Wen M, Li M, Lyu D, Xiao H Chin Med. 2024; 19(1):82.

PMID: 38862959 PMC: 11165817. DOI: 10.1186/s13020-024-00959-1.


SGLT1: A Potential Drug Target for Cardiovascular Disease.

Zhao M, Li N, Zhou H Drug Des Devel Ther. 2023; 17:2011-2023.

PMID: 37435096 PMC: 10332373. DOI: 10.2147/DDDT.S418321.


New Progress in the Molecular Regulations and Therapeutic Applications in Cardiac Oxidative Damage Caused by Pressure Overload.

Shi X, Dorsey A, Qiu H Antioxidants (Basel). 2022; 11(5).

PMID: 35624741 PMC: 9137593. DOI: 10.3390/antiox11050877.


References
1.
Meng L, Uzui H, Guo H, Tada H . Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep. 2018; 17(5):6887-6892. DOI: 10.3892/mmr.2018.8688. View

2.
Sun Z, Chai Q, Zhang Z, Lu D, Meng Z, Wu W . Inhibition of SGLT1 protects against glycemic variability-induced cardiac damage and pyroptosis of cardiomyocytes in diabetic mice. Life Sci. 2021; 271:119116. DOI: 10.1016/j.lfs.2021.119116. View

3.
Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

4.
Kuroda J, Ago T, Matsushima S, Zhai P, Schneider M, Sadoshima J . NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010; 107(35):15565-70. PMC: 2932625. DOI: 10.1073/pnas.1002178107. View

5.
Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View